EMEA-002826-PIP01-20-M03
Table of contents
Key facts
Invented name |
Veklury
|
Active substance |
remdesivir
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0221/2022
|
PIP number |
EMEA-002826-PIP01-20-M03
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019 (COVID-19)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|